GlassScriptPhysician profile
Donna M Murphy
NPI 1083653364
$3,747.52
in general payments reported to CMS, 2019-2025
29 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,126 · 2022: $722 · 2023: $903 · 2024: $441 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,899.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $573.70 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $503.05 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $387.70 | 2021-2025 | |
| Glaxosmithkline, LLC. | $230.11 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Kowa Pharmaceuticals America, INC. | $209.07 | 2021-2022 | |
| Novo Nordisk INC | $206.72 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $193.05 | 2021-2025 | Otezla, Repatha, Otezla |
| Amarin Pharma, INC. | $185.60 | 2021-2023 | |
| Pfizer INC. | $166.28 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.91 | 2021-2022 | |
| Relievant Medsystems, INC. | $113.68 | 2023 | Intracept |
| Merck Sharp & Dohme LLC | $105.91 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Renalytix Ai, INC. | $89.71 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Esperion Therapeutics, INC. | $84.62 | 2021-2025 | Nexletol |
| Bausch Health US, LLC | $68.85 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $59.71 | 2021-2024 | Xarelto |
| Hikma Pharmaceuticals USA | $51.89 | 2023 | Ryaltris |
| Bayer Healthcare Pharmaceuticals INC. | $50.02 | 2023-2024 | |
| Lundbeck LLC | $49.94 | 2024-2025 | Rexulti |
| Eisai INC. | $44.46 | 2021-2022 | |
| Astellas Pharma US INC | $44.03 | 2023 | Veozah |
| Vivus LLC | $37.49 | 2021-2023 | Qsymia |
| Celltrion USA INC. | $32.50 | 2025 | Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.02 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.92 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.90 | 2023 | Quviviq |
| Exact Sciences Corporation | $18.87 | 2023 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $17.95 | 2022 | |
| Genentech USA, INC. | $16.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.